Thrivent Financial for Lutherans Decreases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Thrivent Financial for Lutherans decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 6.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 36,223 shares of the company’s stock after selling 2,417 shares during the period. Thrivent Financial for Lutherans’ holdings in Pacira BioSciences were worth $545,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PCRX. GAMMA Investing LLC lifted its position in shares of Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after buying an additional 932 shares in the last quarter. Innealta Capital LLC purchased a new position in shares of Pacira BioSciences during the 2nd quarter valued at approximately $50,000. nVerses Capital LLC lifted its position in shares of Pacira BioSciences by 800.0% during the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock valued at $51,000 after buying an additional 1,600 shares in the last quarter. CWM LLC lifted its position in shares of Pacira BioSciences by 713.6% during the 3rd quarter. CWM LLC now owns 6,517 shares of the company’s stock valued at $98,000 after buying an additional 5,716 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Pacira BioSciences during the 2nd quarter valued at approximately $113,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. JPMorgan Chase & Co. restated an “underweight” rating and issued a $10.00 price objective (down previously from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Jefferies Financial Group raised their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Piper Sandler lowered Pacira BioSciences from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $42.00 to $11.00 in a report on Monday, August 12th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Finally, StockNews.com lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and an average price target of $23.50.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $19.09 on Thursday. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $35.95. The company has a market cap of $881.44 million, a PE ratio of -9.40 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The business has a 50-day simple moving average of $16.68 and a 200-day simple moving average of $19.56.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.